Glucagon-Like Peptide-1, commonly known as GLP-1, is a hormone that naturally occurs in the body. It plays a crucial role in regulating both blood sugar levels and appetite. Recently, GLP-1 receptor agonists, which are medications that mimic the effects of this hormone, have gained attention for their potential in treating type-2 diabetes and facilitating weight loss.
GLP-1 drugs work by activating specific receptors in the body. This action slows down the emptying of the stomach, reduces appetite, and enhances insulin secretion. As a result, these drugs help in lowering food intake and improving blood sugar control. In India, new GLP-1-based medications such as Wegovy and Mounjaro have been introduced, although there are challenges related to their effectiveness, cost, access, and long-term outcomes.
India faces a significant challenge with over 70% of its adult population being overweight or obese, and more than 100 million individuals suffering from diabetes. While GLP-1 drugs can assist in addressing these issues, they are not standalone solutions. A comprehensive approach involving a balanced diet, regular exercise, and behavioral changes is essential for effective management.
Like any medication, GLP-1 drugs come with potential side effects. Common ones include nausea, vomiting, diarrhea, stomach pain, and loss of appetite. There are also less frequent but serious risks such as pancreatitis, thyroid concerns, and gallbladder issues. Women of childbearing age should use these medications with medical supervision due to uncertain long-term effects.
The affordability of GLP-1 drugs remains a significant barrier in India. For example, the monthly cost of Wegovy at 0.25 mg is approximately ₹17,345, while the highest dose of 2.4 mg costs around ₹26,015. These drugs are imported and patented, leading to high retail prices despite relatively low production costs. Indian pharmaceutical companies are working on developing more affordable versions, but these are still a few years away.
There is a growing global demand for GLP-1 drugs due to their effectiveness in treating multiple conditions such as obesity, type-2 diabetes, PCOS, and even reducing heart risks. This multifaceted benefit has led to worldwide shortages and increased pricing. The demand is reflected in the sales figures, with Novo Nordisk’s Wegovy surpassing $1.5 billion in 2024.
India faces several challenges in leveraging GLP-1 drugs for health improvement. These include high costs and limited insurance coverage, supply constraints, regulatory delays, public misconceptions of pills as quick fixes, and inadequate lifestyle support resources such as dietitians and fitness access. Additionally, there is an urban-rural divide in terms of diagnosis and prescription availability.
In conclusion, while GLP-1-based drugs like Wegovy and Mounjaro offer potential benefits in managing diabetes and obesity, they are not magic solutions. The high cost, side effects, and need for sustained use make them inaccessible for many. Ultimately, lifestyle changes remain central to effectively tackling India's rising obesity and diabetes challenges.
Kutos : AI Assistant!
